UNSPSC 51203500: Immunosupressant aziridines

This classification denotes saturated azacyclopropane compounds, called aziridines, that reduce a human host's humoral and/or cell-mediated defense mechanisms against deviant native cells, foreign organisms, or foreign substances (the human immune response and system thereof), thus the term IMMUNOSUPPRESSANT AZIRIDINES.

UNSPSC 51203500 Immunosuppressant aziridines is a Class code with minimal recent activity aligned to its nominal pharmaceutical scope. State and local procurement records show no recent opportunities specifically soliciting immunosuppressant aziridines or related compounds. The code's abstract name — a narrow pharmaceutical active ingredient — does not match the concrete work state and local governments are actually buying under this classification in the current market.

Recent opportunities tagged to this code instead cover broader medical and pharmaceutical procurement: Seminole County, Florida issued an IFB (due July 26, 2023) for naloxone and drug deactivation systems; the City of Tampa issued an IFB (due March 13, 2026) for medical and first aid supplies for its Fire Department Rescue Division; the Texas Health and Human Services Commission issued an RFI (due April 3, 2026) on direct-to-manufacturer pharmacy programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (due March 26, 2026) for generic multi-source pharmaceuticals and over-the-counter products distributed through authorized wholesalers. The mismatch between the code's narrow pharmaceutical-ingredient scope and the actual procurement activity — which centers on emergency medical supplies, naloxone, generic pharmaceuticals, and pharmacy benefit administration — suggests the code captures little relevant current market activity. Issuers include county health departments, municipal fire departments, state health commissions, and multistate cooperative purchasing vehicles. If your firm operates in immunosuppressant pharmaceutical manufacturing or distribution, this code shows insufficient recent state and local demand to support near-term pursuit; activity appears concentrated in broader emergency medicine and generic pharmaceutical supply rather than specialty immunosuppressant compounds.